Scarica l'app Stockscreener
1.83
2.66%
-0.05
Dopo l'orario di chiusura:
1.87
0.04
+2.19%
Precedente Chiudi:
$1.88
Aprire:
$1.8
Volume 24 ore:
57,067
Relative Volume:
0.33
Capitalizzazione di mercato:
$18.94M
Reddito:
$1.85M
Utile/perdita netta:
$-5.26M
Rapporto P/E:
-1.9361
EPS:
-0.9452
Flusso di cassa netto:
-
1 W Prestazione:
+5.78%
1M Prestazione:
-46.02%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.71
$1.91
Intervallo di 1 settimana:
$1.66
$1.92
Portata 52W:
$1.51
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
Nome
20 20 Biolabs Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
1.83 | 18.94M | 1.85M | -5.26M | 0 | -0.9452 |
ABT
Abbott Laboratories
|
102.87 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.54 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.63 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.82 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.05 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
20 20 Biolabs Inc Borsa (AIDX) Ultime notizie
AIDX : 20/20 Biolabs Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
AIDX: 20/20 Biolabs Inc.Financial Overview - Zacks Investment Research
20/20 BioLabs (AIDX) Reports 17% Revenue Growth in 2025 and Eyes Significant Expansion in 2026 with AI-Powered Cancer Detection Blood Tests - Minichart
20/20 BioLabs (AIDX) grows 2025 revenue 17% and narrows annual net loss - Stock Titan
20/20 Biolabs 10-K: Revenues $2.05M, Net Loss $(3.74)M - TradingView
20/20 Biolabs (NASDAQ: AIDX) outlines AI blood tests, longevity and growth - Stock Titan
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress - The Manila Times
Maryland funds firefighter cancer tests as 20/20 lifts margins - Stock Titan
AIDX | 20/20 Biolabs, Inc. Common Institutional Ownership - Quiver Quantitative
20/20 BioLabs announces grants for Maryland fire departments to procure OneTest - TipRanks
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test - The Manila Times
Maryland funds cancer blood tests for more than 1,400 firefighters - Stock Titan
20/20 BioLabs licenses kidney disease prediction technology from ROKIT Healthcare - MSN
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest Multi-Cancer Early Detection Blood Test - Bitget
20/20 BioLabs licenses kidney disease prediction technology By Investing.com - Investing.com Canada
What's going on with 20/20 Biolabs stock? - MSN
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
20/20 BioLabs enters exclusive technology license, access agreement with Rokit - TipRanks
What's Going On With 20/20 Biolabs Stock? - Benzinga
20/20 Biolabs Faces Decline Amid Market Rut - timothysykes.com
20/20 BioLabs licenses kidney disease prediction technology - Investing.com
20/20 Biolabs shares are trading lower after ... - Benzinga
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program - The Manila Times
20/20 BioLabs Announces Exclusive U.S. License Agreement - GlobeNewswire
What is the current Price Target and Forecast for 20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
What date does 20/20 Biolabs Inc.'s (AIDX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
AIDX Stock Price, News & Analysis - Stock Titan
Debt to equity ratio of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
20/20 Biolabs Inc. (AIDX) Total Long Term Debt (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Return On Assets (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Total Expenses (TTM) - zacks.com
20/20 Biolabs Inc. (AIDX) Price Book Value - Zacks Investment Research
Cash per share of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
Michael A. Ross Net Worth (2026) - GuruFocus
Michael Saul Lebowitz Net Worth (2026) - GuruFocus
Jonathan M Cohen Net Worth (2026) - GuruFocus
Prasanth Reddy Net Worth (2026) - GuruFocus
Jiming Zhou Net Worth (2026) - GuruFocus
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies - Sahm
20/20 Biolabs, Inc. Revenue Breakdown – NASDAQ:AIDX - TradingView
Analysts Offer Insights on Healthcare Companies: 20/20 Biolabs, Inc. (AIDX) and Biogen (BIIB) - The Globe and Mail
20/20 BioLabs provides update on protein biomarket technology for MCED - TipRanks
Blood test using proteins aims to catch cancer years earlier than DNA screens - Stock Titan
Jonathan Cohen Discloses Investment at 20/20 Biolabs with 16.8% Stake - TradingView
Full Succeed (AIDX) owns 6.3% — 651,465 shares disclosed in Schedule 13G - Stock Titan
20/20 Biolabs (AIDX) CEO awarded 352,936-share stock option grant - Stock Titan
20/20 Biolabs Inc. (AIDX) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
20/20 Biolabs (AIDX) 10K Form and SEC Filings 2026 - MarketBeat
20/20 Biolabs Inc. (AIDX) Free Cash Flow (TTM) - Zacks Investment Research
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
20/20 Biolabs Inc. (AIDX) Price To Cash Flow - Zacks Investment Research
20 20 Biolabs Inc Azioni (AIDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):